Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
Alibaba Group Holding (NYSE:BABA) soared in its market debut today, trading as much as 46 percent above its initial public offering price of $68 and making the Chinese e-commerce company one of the most valuable companies in the U.S. The stock opened at $92.70 and nearly hit $100 on the New York Stock Exchange.
US stocks were mostly higher on Friday following the Scots voting "no" on independence, and as Alibaba finally began trading on the New York Stock Exchange, opening at a 36% premium from its IPO price.
Cardiome Pharma's (NASDAQ:CRME) (TSE:COM) shares swung higher on Monday even after the specialty pharma company posted a Q2 wider net loss, as revenues surged due to strong sales from its Brinavess cardiology drug on the back of an aggressive marketing and promotional push.
Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) were jumping on Friday as the the FDA has modified the full clinical hold on its TKM-Ebola drug to a partial clinical hold, allowing the biopharmaceutical company to potentially make the drug available to patients infected with the virus.
The company, in a statement released earlier today, told investors it has signed a memorandum of understanding to form a "joint venture distribution agreement" with ACGT Corp and associates, a provider of DNA services in Canada with strong ties to China.
Tweed Marijuana's (CVE:TWD) shares rallied over 5 percent on Thursday after the company said it will be releasing up to 18 additional marijuana varieties beginning next week, for sale in August and September.
Investors interested in Neuralstem recently viewed
- Clinigen Group PLC (AIM: CLIN) .
- Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements
- Medical Australia Limited (ASX: MLA) Medical devices developed, manufactured and distributed in Australia.
- Alliance Pharma (AIM: APH) Prescription branded medicines in the human medical and dental sectors
- Advanced Oncotherapy (AIM: AVO) .